{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T01:26:35Z","timestamp":1760318795964},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,12,14]],"date-time":"2010-12-14T00:00:00Z","timestamp":1292284800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s12032-010-9767-x","type":"journal-article","created":{"date-parts":[[2010,12,15]],"date-time":"2010-12-15T16:41:24Z","timestamp":1292431284000},"page":"193-198","source":"Crossref","is-referenced-by-count":13,"title":["Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker"],"prefix":"10.1007","volume":"29","author":[{"given":"Daniel","family":"Binder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Christin","family":"Buckendahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf-Harto","family":"H\u00fcbner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Schlattmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Temmesfeld-Wollbr\u00fcck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Beinert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Suttorp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,12,14]]},"reference":[{"key":"9767_CR1","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","volume":"101","author":"W Pao","year":"2004","unstructured":"Pao W, et al. EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101:13306\u201311.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9767_CR2","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1158\/1078-0432.CCR-06-0462","volume":"12","author":"DM Jackman","year":"2006","unstructured":"Jackman DM, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12:3908\u201314.","journal-title":"Clin Cancer Res"},{"key":"9767_CR3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1158\/1078-0432.CCR-05-1846","volume":"12","author":"GJ Riely","year":"2006","unstructured":"Riely GJ, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12:839\u201344.","journal-title":"Clin Cancer Res"},{"key":"9767_CR4","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","volume":"361","author":"R Rosell","year":"2009","unstructured":"Rosell R, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958\u201367.","journal-title":"N Engl J Med"},{"key":"9767_CR5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.lungcan.2009.01.014","volume":"66","author":"S Cedres","year":"2009","unstructured":"Cedres S, et al. Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib. Lung Cancer. 2009;66:257\u201361.","journal-title":"Lung Cancer"},{"key":"9767_CR6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"FA Shepherd","year":"2005","unstructured":"Shepherd FA, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123\u201332.","journal-title":"N Engl J Med"},{"key":"9767_CR7","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1097\/JTO.0b013e3181f1c7b0","volume":"5","author":"M Reck","year":"2010","unstructured":"Reck M, et al. Erlotinib in Advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva lung cancer survival treatment study. J Thorac Oncol. 2010;5:1616\u201322.","journal-title":"J Thorac Oncol"},{"key":"9767_CR8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.lungcan.2008.09.001","volume":"64","author":"M Tiseo","year":"2009","unstructured":"Tiseo M, et al. An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy. Lung Cancer. 2009;64:199\u2013206.","journal-title":"Lung Cancer"},{"key":"9767_CR9","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1097\/JTO.0b013e3181bbb2b9","volume":"4","author":"JS Lind","year":"2009","unstructured":"Lind JS, et al. Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity. J Thorac Oncol. 2009;4:1585\u20136.","journal-title":"J Thorac Oncol"},{"key":"9767_CR10","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1097\/JTO.0b013e3181dd1386","volume":"5","author":"WL Yeo","year":"2010","unstructured":"Yeo WL, et al. Erlotinib at a dose of 25\u00a0mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol. 2010;5:1048\u201353.","journal-title":"J Thorac Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9767-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-010-9767-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9767-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T02:22:51Z","timestamp":1559442171000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-010-9767-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,14]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["9767"],"URL":"https:\/\/doi.org\/10.1007\/s12032-010-9767-x","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,14]]}}}